[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369238-105":59,"doc-detail-369238-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","mechanisms-of-anti-pd-therapy-resistance-in-digestive-system-neoplasms-review-article","Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms - Review Article","","Digestive system neoplasms are highly heterogeneous and deploy complex resistance mechanisms that weaken anti-programmed cell death protein (PD) therapies. The tumor microenvironment (TME) drives tumor progression and immune escape beyond providing growth support, via pathways including modulation of heritable gene expression and interaction with gut microbiota. This review focuses on immune-mediated resistance, microbial crosstalk, metabolism, and epigenetics, highlighting tumor-specific features. It also outlines current therapeutic strategies promising synergy with cancer immune normalization approaches to guide intervention development.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mechanisms-of-anti-pd-therapy-resistance-in-digestive-system-neoplasms-review-article/369238/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mechanisms-of-anti-pd-therapy-resistance-in-digestive-system-neoplasms-review-article/369238.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why do anti-PD therapies often fail in digestive system neoplasms?","Question",{"text":112,"@type":113},"Digestive tumors develop intricate resistance mechanisms. The tumor microenvironment helps promote progression and immune escape, reducing anti-PD therapy effectiveness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What roles do the tumor microenvironment and gut microbiota play?",{"text":117,"@type":113},"The tumor microenvironment facilitates tumor progression and immune escape through diverse pathways. It also engages in complex interplay with the gut microbiota, contributing to resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What resistance mechanisms does the review emphasize?",{"text":121,"@type":113},"The review highlights immune-mediated resistance, microbial crosstalk, metabolism, and epigenetics. It also stresses the significance of the tumor immune microenvironment (TIME).",{"name":123,"@type":110,"acceptedAnswer":124},"How might future therapies improve outcomes?",{"text":125,"@type":113},"The review discusses current therapeutic strategies that may combine with cancer immune normalization therapies. The goal is to restore or enhance anti-tumor immunity by overcoming immune evasion mechanisms.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},369238,1790245973,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Send Orders for Reprints [to reprints@benthamscience.net](to reprints@benthamscience.net)  \n1  \nRecent Patents on Anti-Cancer Drug Discovery, 2025, 20, 1-25  \nREVIEW ARTICLE  \nMechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms  \nRecent Pa ten ts on An t i-Cancer DrugDiscovery  \nYuxia Wu 1,\\#, Xiangyan Jiang 1,\\# , Zeyuan Yu 1,*, Zongrui Xing 1, Yong Ma 1 and Huiguo Qing 1 1Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu, China  \n© 2025 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 [https://creativecommons.org/licenses/by/4.0/legalcode](https://creativecommons.org/licenses/by/4.0/legalcode)  \nAbstract: Digestive system neoplasms are highly heterogeneous and exhibit complex resistance mechanisms that render anti-programmed cell death protein (PD) therapies poorly effective. The tumor microenvironment (TME) plays a pivotal role in tumor development, apart from supplying energy for tumor proliferation and impeding the body's anti-tumor immune response, the TME actively facilitates tumor progression and immune escape via diverse pathways, which include the modulation of heritable gene expression alterations and the intricate interplay with the gut microbiota. In this review, we aim to elucidate the mechanisms underlying drug resistance in digestive tumors, focusing on immune-mediated resistance, microbial crosstalk, metabolism, and epigenetics. We will highlight the unique characteristics of each digestive tumor and emphasize the significance of the tumor immune microenvironment (TIME) . Furthermore, we will discuss the current therapeutic strategies that hold promise for combination with cancer immune normalization therapies. This review aims to provide a thorough understanding of the resistance mechanisms in digestive tumors and offer insights into potential therapeutic interventions.  \nKeywords: Immunotherapy resistance, normalization cancer immunotherapy, PD-1/B7-H1, anti-PD-1/PD-L1 therapy, digestive system neoplasms, pancreatic cancer.  \n1. INTRODUCTION  \nMalignant tumors of the digestive system are widespread and pose significant health risks with high rates of illness and death. According to the latest statistics from the American Cancer Society, pancreatic cancer (PC) (12%) liver and esophageal cancer (21%) have the lowest survival rates. Additionally, colorectal cancer (CRC) and PC are the second and third most common causes of cancer-related deaths in men and women, respectively [1] . The traditional treatment strategies for gastrointestinal (GI) malignancies include surgical resection, radiation therapy, chemotherapy, and molecular-targeted drug therapy. Despite significant improvements in patient survival, high rates of metastasis and recurrence persist after treatment, resulting in poor overall survival. In recent years, immunotherapy has rapidly developed and gained attention for clinical applications owing to its promising anti-tumor effects. In contrast to conventional treatments, immunotherapy kills cancer cells by activating anti-tumor immunity and specifically targets cancer antigens to prevent normal cells from being attacked [2, 3] . Currently, Immune checkpoint inhibitors (ICIs), primarily PD-1/PD-L1 blockers have shown remarkable success in treating a variety of malignancies, and their efficacy in many clinical trials has advanced the treatment of CRC, gastric cancer (GC), and other GI tumors [4-7] . Anti-PD therapies specifically target the  \n*Address correspondence to this author at the Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu, China; Tel:  \n+86 15002637155; [E-mail: yuzeyuan-06@163.com](E-mail: yuzeyuan-06@163.com)  \n\\#These authors contributed equally to this work.  \n2212-3917/25  \nrestoration of lost anti-tumor immunity by addressing immune evasion mechanisms in the TME, with the aim to normalize cancer immunity. This presents significant opport","cbCaiqJO66y8r5jK","https://ap.wps.com/l/cbCaiqJO66y8r5jK","pdf",8533029,25,"English","# Introduction\n# Mechanism of Action of Anti-PD Therapy","[{\"question\":\"Why do anti-PD therapies often fail in digestive system neoplasms?\",\"answer\":\"Digestive tumors develop intricate resistance mechanisms. The tumor microenvironment helps promote progression and immune escape, reducing anti-PD therapy effectiveness.\"},{\"question\":\"What roles do the tumor microenvironment and gut microbiota play?\",\"answer\":\"The tumor microenvironment facilitates tumor progression and immune escape through diverse pathways. It also engages in complex interplay with the gut microbiota, contributing to resistance.\"},{\"question\":\"What resistance mechanisms does the review emphasize?\",\"answer\":\"The review highlights immune-mediated resistance, microbial crosstalk, metabolism, and epigenetics. It also stresses the significance of the tumor immune microenvironment (TIME).\"},{\"question\":\"How might future therapies improve outcomes?\",\"answer\":\"The review discusses current therapeutic strategies that may combine with cancer immune normalization therapies. The goal is to restore or enhance anti-tumor immunity by overcoming immune evasion mechanisms.\"}]","Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms - Review Article | PDF",1790181561,63,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff954f3fb4744e12b420a3af90de6ee1.webp",983,1272,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18d364455c77729d3ab7a434afe3fc31.webp",982,1270,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f9b2f20e534e6158d368aa6211593d5.webp",981,1269,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a423f30265cb667775064238ba378fa.webp",980,1268]